drugset

drugset / Trial / NCT01226797

Safety And Efficacy Of Oral PF-4136309 In Patients With Chronic Hepatitis C Infection And Abnormal Liver Enzymes

NCT01226797 ↗

Phase 2 Terminated 24 enrolled Pfizer

RandomizedQuadruple-blindTreatment

Summary

This study will evaluate the effect of PF-04136309 in patients with chronic hepatitic C virus infection and abnormal liver enzymes.

Timeline

Start: 2011-01-17
Primary completion: 2012-02-09
Completion: 2012-02-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	PF-4136309	Small molecule	500 mg	Oral

Indications